Physician profile
Gary Keller
NPI 1851371587
$11,583.51
in general payments reported to CMS, 2019-2025
34 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $499 · 2021: $318 · 2022: $585 · 2023: $533 · 2024: $8,988 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $8,440 · Food and Beverage: $1,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $8,440.00 |
| Food and Beverage | $1,219.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $8,457.77 | 2022-2024 | Restrata Wound Matrix |
| Smith+Nephew, INC. | $976.07 | 2019-2025 | Grafix Pl, Oasis, Collagenase Santyl |
| Organogenesis INC. | $517.47 | 2020-2023 | Puraply |
| Stryker Corporation | $265.75 | 2019-2024 | Salvation, Aequalis Ascend Flex, Aequalis Perform Reversed |
| Treace Medical Concepts, INC. | $143.75 | 2024 | |
| Sebela Pharmaceuticals INC. | $121.24 | 2020-2023 | Naftin |
| Kci USA, INC. | $119.75 | 2020-2022 | |
| Integra Lifesciences Corporation | $112.62 | 2020-2024 | Integra, Tenoglide, Primatrix |
| Kerecis Limited | $111.78 | 2020-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Ets Wound Care LLC | $90.94 | 2023-2024 | Mirragen Advanced Wound Matrix |
| Paratek Pharmaceuticals, INC. | $71.92 | 2020-2023 | Nuzyra |
| Medtronic Vascular, INC. | $71.49 | 2019 | |
| Polynovo North America LLC | $70.60 | 2024-2025 | Novosorb Btm |
| Solventum Corporation | $46.05 | 2024-2025 | Promogran Prisma, Kerramax Care, Activ.A.C. |
| Melinta Therapeutics, LLC | $37.54 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $28.93 | 2023-2024 | Tirosint, Licart, Licart |
| Djo, LLC | $28.34 | 2024 | Cmf |
| Kowa Pharmaceuticals America, INC. | $27.03 | 2022 | |
| Osiris Therapeutics INC. | $23.99 | 2019 | |
| Reprise Biomedical, INC. | $23.13 | 2024 | Miro3d |
| Innovation Technologies INC | $23.04 | 2022 | |
| Grt US Holding, INC. | $22.11 | 2022 | |
| Glenmark Therapeutics INC. | $20.00 | 2019 | |
| Averitas Pharma INC. | $18.83 | 2024 | Qutenza |
| Acell, INC. | $18.73 | 2019 | |
| Zimmer Biomet Holdings, INC. | $18.16 | 2020 | |
| Bioventus LLC | $18.10 | 2021 | |
| Stimwave Technologies Incorporated | $16.00 | 2021 | |
| Misonix INC | $15.30 | 2019 | |
| Amniox Medical, INC. | $14.67 | 2019 | |
| Abbvie INC. | $13.73 | 2022 | |
| Biotissue Holdings INC. | $13.32 | 2022 | |
| Urgo Medical North America, LLC | $13.15 | 2023 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Aroa Biosurgery Incorporated | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.